NeuroPace, Inc.

<div class="infobox">
<div class="infobox-header">NeuroPace, Inc.</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>NASDAQ: NPCE</td></tr>
<tr><th>Headquarters</th><td>San Francisco Bay Area, California, USA</td></tr>
<tr><th>Founded</th><td>2015</td></tr>
<tr><th>Focus</th><td>Alpha-synuclein aggregation inhibitors</td></tr>
<tr><th>Status</th><td>Clinical stage</td></tr>
<tr><th>Market Cap</th><td>~$200M (2026)</td></tr>
</table>
</div>
</div>

Overview

<div class="infobox">
<div class="infobox-header">NeuroPace, Inc.</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>NASDAQ: NPCE</td></tr>
<tr><th>Headquarters</th><td>San Francisco Bay Area, California, USA</td></tr>
<tr><th>Founded</th><td>2015</td></tr>
<tr><th>Focus</th><td>Alpha-synuclein aggregation inhibitors</td></tr>
<tr><th>Status</th><td>Clinical stage</td></tr>
<tr><th>Market Cap</th><td>~$200M (2026)</td></tr>
</table>
</div>
</div>

Overview

NeuroPace, Inc. is a clinical-stage pharmaceutical company focused on developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on [Parkinson's disease](/diseases/parkinsons-disease) and related synucleinopathies["@alpha_syn_oligomer"].[@alpha_syn_oligomer] The company was founded in 2015 with a mission to target the fundamental pathophysiology of alpha-synuclein aggregation, the protein whose misfolding and accumulation underlies the pathogenesis of [Parkinson's disease](/diseases/parkinsons-disease), [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies), and multiple system atrophy["1"].

Unlike many competitors in the alpha-synuclein space who are developing antibody-based approaches targeting extracellular aggregates, NeuroPace has taken a differentiated small molecule approach focused on inhibiting the formation and propagation of toxic alpha-synuclein oligomers inside [neurons](/entities/neurons). This intracellular targeting strategy addresses the earliest stages of protein misfolding—before toxic species can spread between cells and before large Lewy bodies form["2"].

Scientific Rationale

The Alpha-Synuclein Problem

Alpha-synuclein is a 140-amino-acid protein encoded by the [SNCA](/genes/snca) gene that is highly enriched in presynaptic terminals where it participates in synaptic vesicle trafficking and neurotransmitter release. In its native state, alpha-synuclein exists as an intrinsically disordered monomer. However, in Parkinson's disease and related disorders, this protein undergoes a pathological transformation:

This aggregation cascade is central to the pathogenesis of Parkinson's disease, and substantial evidence now suggests that soluble oligomeric forms of alpha-synuclein—rather than the mature fibrils in Lewy bodies—are the most toxic species[3].

Oligomer Toxicity

Alpha-synuclein oligomers have been shown to:

• Disrupt mitochondrial function: By inserting into mitochondrial membranes and impairing electron transport chain complex I activity
• Cause oxidative stress: Through metal ion binding and reactive oxygen species generation
• Perturb synaptic function: By interfering with synaptic vesicle recycling and neurotransmitter release
• Induce endoplasmic reticulum stress: Activating the unfolded protein response
• Trigger inflammatory responses: Through microglial activation and cytokine release

Why Small Molecules?

NeuroPace's small molecule approach offers several potential advantages over antibody-based strategies:

| Feature | Small Molecule (NeuroPace) | Antibody Approach |
|---------|---------------------------|-------------------|
| Target location | Intracellular (cytosol) | Extracellular (CSF, plasma) |
| BBB penetration | Brain-penetrant | Limited brain exposure |
| Dosing | Oral administration | IV infusion |
| Manufacturing | Cost-effective synthesis | Complex biologics |
| Target | Oligomer formation | Pre-formed aggregates |

The ability to target intracellular alpha-synuclein directly where misfolding initiates represents the key differentiator for NeuroPace's approach[5].

Lead Program: NPT200-1

Mechanism of Action

NPT200-1 is a novel small molecule designed to inhibit the formation and propagation of toxic alpha-synuclein oligomers through a precision binding mechanism. The compound interacts with specific domains on the alpha-synuclein protein to:

Preclinical studies have demonstrated that NPT200-1 can reduce alpha-synuclein oligomer formation in cellular models by up to 80% while maintaining favorable pharmacokinetic properties for brain exposure[6].

Development Status

NPT200-1 is currently in Phase 1 clinical development:

• Phase 1a: Single ascending dose study in healthy volunteers (completed)
• Phase 1b: Multiple ascending dose study in healthy volunteers (completed)
• Phase 1c: First-in-patient study in early Parkinson's disease patients (ongoing)

Clinical Development Strategy

NeuroPace's clinical development strategy follows a staged approach:

| Phase | Focus | Timeline |
|-------|-------|----------|
| Phase 1 | Safety, PK/PD, target engagement | 2024-2025 |
| Phase 2a | Proof-of-concept in early PD | 2026-2027 |
| Phase 2b | Dose-optimization in broader PD | 2027-2028 |
| Phase 3 | Registration trials | 2029-2031 |

The company is exploring biomarker-driven patient selection to enrich for patients most likely to benefit from therapy, potentially including those with specific genetic risk factors or evidence of rapid disease progression[8].

Therapeutic Approach

Core Pillars

NeuroPace's therapeutic approach is built on three pillars:

1. Alpha-Synuclein Oligomer Inhibition

The company's core focus is preventing the formation of toxic oligomers at the earliest possible stage. This approach differs from strategies targeting:

• Antibodies: Target extracellular aggregates that have already formed
• Fibril breakers: Target mature fibrils after oligomerization has occurred

2. Small Molecule Brain Penetration

NeuroPace has invested heavily in optimizing brain penetration through:

• Lipinski-compliant properties: Molecular weight <500 Da, limited H-bond donors/acceptors
• P-gp avoidance: Minimizing substrate affinity for efflux transporters
• Optimized logD: Balancing lipophilicity for membrane passage with solubility
• Sustained brain exposure: Achieving trough brain concentrations above the IC50 for 24 hours

3. Disease Modification

All of NeuroPace's programs are designed with disease modification as the goal. Unlike symptomatic treatments that address dopamine deficiency (levodopa, dopamine agonists), disease-modifying therapies aim to slow or halt the underlying pathological progression. The company measures success through:

• Motor progression: Less reliance on dopaminergic medications over time
• Non-motor symptoms: Preservation of cognitive function, autonomic function
• Biomarker progression: Slowing of alpha-synuclein pathology accumulation
• Functional endpoints: Maintaining activities of daily living

Science and Technology

Alpha-Synuclein Biology

NeuroPace's approach targets the fundamental biology of alpha-synuclein misfolding and aggregation. The company's research encompasses:

Oligomer Formation Kinetics

Understanding the kinetics of alpha-synuclein aggregation is essential for identifying optimal intervention points:

NPT200-1 is designed to intercept the nucleation and early oligomer growth phases[11].

Membrane Interaction

Alpha-synuclein interacts with neuronal membranes in ways that contribute to toxicity:

• Membrane binding: The N-terminal domain binds to synaptic vesicles
• Membrane disruption: Oligomers can form pores in membranes
• Mitochondrial association: Preferential binding to mitochondrial membranes

Cell-to-Cell Propagation

The prion-like spread of alpha-synuclein pathology between neurons is increasingly recognized as a key driver of disease progression:

• Release: Oligomers and fibrils are released from affected neurons
• Uptake: Neighboring neurons take up pathological species via endocytosis
• templating: Internalized seeds template the misfolding of endogenous alpha-synuclein
• Propagation: The cycle repeats, spreading pathology throughout the brain

Discovery Platform

NeuroPace has built an integrated discovery platform that combines:

| Capability | Application |
|------------|-------------|
| High-throughput screening | Identifying initial hit compounds |
| Structure-based design | Optimizing binding to alpha-synuclein |
| Cellular assays | Measuring oligomer inhibition in neurons |
| Animal models | Validating efficacy in PD models |
| Biomarker development | Developing patient selection tools |

This platform has generated a pipeline of backup compounds beyond NPT200-1, providing development optionality.

Pipeline Overview

| Program | Mechanism | Indication | Development Stage |
|---------|-----------|------------|-------------------|
| NPT200-1 | Alpha-synuclein oligomer inhibitor | Parkinson's disease | Phase 1 |
| NPT200-2 | Alpha-synuclein oligomer inhibitor | Dementia with Lewy bodies | Preclinical |
| NPT300-1 | Alpha-synuclein aggregation inhibitor | Multiple system atrophy | Discovery |
| NPT400-1 | Synuclein clearance enhancer | Parkinson's disease | Discovery |

Competitive Landscape

NeuroPace competes in a rapidly evolving alpha-synuclein therapeutic space with several other approaches:

Antibody-Based Approaches

| Company | Program | Mechanism | Development Stage |
|---------|---------|-----------|-------------------|
| Roche/Genentech | Prasinezumab | Anti-alpha-synuclein antibody | Phase 2 |
| Prothena | Cinpanemab (PRX002) | Anti-alpha-synuclein antibody | Phase 2 |
| Biogen | BIIB122 | Anti-alpha-synuclein antibody | Phase 1 |

Antibody approaches target extracellular alpha-synuclein and require periodic IV infusions. While they have demonstrated target engagement, they do not address intracellular oligomer formation[14].

LRRK2 Inhibitors

| Company | Program | Mechanism | Development Stage |
|---------|---------|-----------|-------------------|
| Biogen | BIIB122/DNL151 | LRRK2 kinase inhibitor | Phase 2 |
| Denali Therapeutics | DNL151 | LRRK2 kinase inhibitor | Phase 2 |
| Novartis | LDN-0117561 | LRRK2 kinase inhibitor | Phase 1 |

LRRK2 inhibitors target a different pathway (leucine-rich repeat kinase 2) and may provide complementary benefits. Interestingly, LRRK2 inhibition may also reduce alpha-synuclein pathology through effects on lysosomal function[15].

Other Small Molecule Approaches

| Company | Program | Mechanism | Development Stage |
|---------|---------|-----------|-------------------|
| Aprinoia | AP-101 | Alpha-synuclein aggregation inhibitor | Phase 1 |
| Caraway Therapeutics | Small molecules | Alpha-synuclein modulators | Discovery |

NeuroPace's differentiated oligomer-focused mechanism provides a unique position in this competitive landscape.

Business Strategy

Partnership Model

NeuroPace has pursued a hybrid development strategy:

• Internal development: Retained full rights to NPT200-1 through Phase 2
• Future partnership: Likely to seek a major pharmaceutical partner for Phase 3 and global commercialization

Funding History

| Round | Year | Amount | Lead Investors |
|-------|------|--------|----------------|
| Series A | 2016 | $25M | ARCH Venture Partners |
| Series B | 2018 | $45M | The Columnist, OrbiMed |
| Series C | 2020 | $70M | Andreessen Horowitz, GV |
| IPO | 2021 | $85M | Nasdaq: NPCE |

The company's public market valuation has fluctuated significantly, reflecting the challenges of clinical development in the neurodegenerative space.

Relevance to NeuroWiki

NeuroPace represents an important case study in the development of disease-modifying therapies for Parkinson's disease:

• Mechanistic focus: Illustrates the importance of targeting specific pathological proteins
• Small molecule approach: Demonstrates the potential for brain-penetrant oral therapies
• Biomarker development: Shows the importance of patient selection and target engagement biomarkers
• Competitive landscape: Represents one approach among many in the alpha-synuclein field

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
• [Alpha-Synuclein](/proteins/alpha-synuclein)](/proteins)
• [Alpha-Synuclein Therapeutics Pipeline](/companies/alpha-synuclein-therapeutics)](/therapeutics)
• [PD Disease-Modifying Therapies](/companies/pd-disease-modifying-therapies)
• [Small Molecule Parkinson's Treatments](/companies/small-molecule-pd-treatments)

External Links

• [NeuroPace Website](https://www.neuropace.com/)
• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [Investor Presentations](https://ir.neuropace.com)

References